These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17725208)

  • 41. The prevalence of anemia in patients with chronic kidney disease.
    McClellan W; Aronoff SL; Bolton WK; Hood S; Lorber DL; Tang KL; Tse TF; Wasserman B; Leiserowitz M
    Curr Med Res Opin; 2004 Sep; 20(9):1501-10. PubMed ID: 15383200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
    Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Feyzi JM; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill JB; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R;
    N Engl J Med; 2009 Nov; 361(21):2019-32. PubMed ID: 19880844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
    Gentil MA; Pérez-Valdivia MA; González-Roncero FM; López-Mendoza M; Cabello V; Bernal G; Suñer M; Pereira P
    Transplant Proc; 2008 Nov; 40(9):2916-8. PubMed ID: 19010146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anemia management in chronic kidney disease.
    Gillespie BS; Inrig JK; Szczech LA
    Hemodial Int; 2007 Jan; 11(1):15-20. PubMed ID: 17257350
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
    Vaziri ND; Zhou XJ
    Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
    [No Abstract]   [Full Text] [Related]  

  • 46. Correction of anemia--payoffs and problems.
    Remuzzi G; Ingelfinger JR
    N Engl J Med; 2006 Nov; 355(20):2144-6. PubMed ID: 17108347
    [No Abstract]   [Full Text] [Related]  

  • 47. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?
    Covic A; Seica A; Gusbeth-Tatomir P; Goldsmith D
    J Nephrol; 2008; 21(4):478-84. PubMed ID: 18651536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
    Lefebvre P; Vekeman F; Sarokhan B; Enny C; Provenzano R; Cremieux PY
    Curr Med Res Opin; 2006 Oct; 22(10):1929-37. PubMed ID: 17022852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
    Solomon SD; Uno H; Lewis EF; Eckardt KU; Lin J; Burdmann EA; de Zeeuw D; Ivanovich P; Levey AS; Parfrey P; Remuzzi G; Singh AK; Toto R; Huang F; Rossert J; McMurray JJ; Pfeffer MA;
    N Engl J Med; 2010 Sep; 363(12):1146-55. PubMed ID: 20843249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treating anemia at different stages of renal disease.
    Locatelli F; Del Vecchio L; Pozzoni P
    J Nephrol; 2007; 20 Suppl 12():S33-8. PubMed ID: 18050140
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
    Winkelmayer WC
    J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
    [No Abstract]   [Full Text] [Related]  

  • 52. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

  • 53. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 54. The target hemoglobin in patients with chronic kidney disease.
    Singh AK
    Nephrol News Issues; 2006 Dec; 20(13):29-30. PubMed ID: 17168056
    [No Abstract]   [Full Text] [Related]  

  • 55. Evidence for optimal hemoglobin targets in chronic kidney disease.
    Navaneethan SD; Bonifati C; Schena FP; Strippoli GF
    J Nephrol; 2006; 19(5):640-7. PubMed ID: 17136694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients.
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):410-6. PubMed ID: 19414943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Tonelli M; Garg AX; Pellegrini F; Ravani P; Jardine M; Perkovic V; Graziano G; McGee R; Nicolucci A; Tognoni G; Strippoli GF
    Ann Intern Med; 2010 Jul; 153(1):23-33. PubMed ID: 20439566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health-related quality of life and hemoglobin levels in chronic kidney disease patients.
    Finkelstein FO; Story K; Firanek C; Mendelssohn D; Barre P; Takano T; Soroka S; Mujais S
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):33-8. PubMed ID: 18987300
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
    Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
    J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.